SCHEMBL17137484

SCHEMBL17137484

COC(=O)N(C)C(=O)c1nc2ccc(Br)cc2n1C(=O)OC(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 2/20 0.36
AURKA O14965 3/20 0.36
CDK2 P24941 3/20 0.36
BACE1 P56817 1/20 0.35
CCNB2 O95067 1/20 0.34
CDK1 P06493 1/20 0.34
CCNB1 P14635 1/20 0.34
GSK3B P49841 1/20 0.34
CCNB3 Q8WWL7 1/20 0.34
CCNA2 P20248 2/20 0.34
TTK P33981 2/20 0.34
NR1H2 P55055 4/20 0.33
IRAK4 Q9NWZ3 1/20 0.33
RAB9A P51151 2/20 0.33
MMP2 P08253 1/20 0.33
MMP9 P14780 1/20 0.33
MMP8 P22894 1/20 0.33
MMP13 P45452 1/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17137749 0.93 CCNB2 (0.36) USP30AURKACDK2BACE1CCNB2
SCHEMBL4303176 0.85 L3MBTL1 (0.38) IRAK4RAB9AMMP2MMP9MMP8
SCHEMBL6120980 0.80 BACE1 (0.40) USP30AURKACDK2BACE1CCNB2
SCHEMBL17137482 0.80 KDM4E (0.39) USP30BACE1NR1H2MEN1KMT2A
SCHEMBL482136 0.79 BACE1 (0.40) USP30AURKACDK2BACE1CCNB2
SCHEMBL30847402 0.78 USP30 (0.39) USP30BACE1CCNB2CDK1CCNB1
SCHEMBL12158 0.78 USP30 (0.39) USP30BACE1CCNB2CDK1CCNB1
SCHEMBL4309932 0.77 L3MBTL1 (0.38) IRAK4RAB9AMMP2MMP9MMP8
SCHEMBL14920239 0.77 BACE1 (0.41) USP30BACE1CCNB2CDK1CCNB1
SCHEMBL31267738 0.77 BACE1 (0.45) USP30BACE1RAB9AMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150284335-A1 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150284335-A1 Benzoimidazoles as prolyl hydroxylase inhibitors EGLN3, EGLN2, P4HA1 USP30 1556/4885AURKA 4517/4885CDK2 986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.